Study #2017-0064
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Ly
MD Anderson Study Status
Not Accepting
Treatment Agent
ibrutinib, rituximab, placebo to match ibrutinib
Description
The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve participants with follicular lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Follicular Lymphoma
Study phase:
Phase III
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-714-4981
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.